Search

Your search keyword '"Nanda, Kavinderjit S."' showing total 24 results
Start Over Author "Nanda, Kavinderjit S."
24 results on '"Nanda, Kavinderjit S."'

3. Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps

Author

Burgess, Nicholas G, Pellise, Maria, Nanda, Kavinderjit S, Hourigan, Luke F, Zanati, Simon A, Brown, Gregor J, Singh, Rajvinder, Williams, Stephen J, Raftopoulos, Spiro C, Ormonde, Donald, Moss, Alan, Byth, Karen, PʼNg, Heok, McLeod, Duncan, Bourke, Michael J, Mahajan, Hema, Bettington, Mark, Clouston, Andrew, Dow, Chris, Bhathal, Prithi, Pham, Alan, Ruszkiewicz, Andrew, McGivern, Andrina, and Kumarasinghe, Priyanthi

Published
2016
Full Text
View/download PDF

8. Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps

Author

Burgess, Nicholas G, primary, Pellise, Maria, additional, Nanda, Kavinderjit S, additional, Hourigan, Luke F, additional, Zanati, Simon A, additional, Brown, Gregor J, additional, Singh, Rajvinder, additional, Williams, Stephen J, additional, Raftopoulos, Spiro C, additional, Ormonde, Donald, additional, Moss, Alan, additional, Byth, Karen, additional, P'Ng, Heok, additional, McLeod, Duncan, additional, and Bourke, Michael J, additional

Published
2015
Full Text
View/download PDF

16. 505 Comparison of Large Sessile Serrated Adenoma Characteristics With Conventional Advanced Mucosal Neoplasia Resected by Wide Field Endoscopic Mucosal Resection in a Multicenter Prospective Cohort

Author

Burgess, Nicholas G., primary, Nanda, Kavinderjit S., additional, Williams, Stephen J., additional, Singh, Rajvinder, additional, Hourigan, Luke F., additional, Zanati, Simon a., additional, Brown, Gregor J., additional, Mcleod, Duncan J., additional, and Bourke, Michael J., additional

Published
2013
Full Text
View/download PDF

17. Su1036 Phenotypic Expression of Large (≥ 20mm) Sessile Serrated Adenomas of the Colon As a Predictor of High Grade Dysplasia or Colorectal Cancer in a Multicenter Prospective Cohort

Author

Nanda, Kavinderjit S., primary, Burgess, Nicholas G., additional, Williams, Stephen J., additional, Singh, Rajvinder, additional, Hourigan, Luke F., additional, Zanati, Simon A., additional, Brown, Gregor J., additional, Ward, Robyn L., additional, Sonson, Rebecca, additional, Acharya, Priya, additional, Byth, Karen, additional, and Bourke, Michael J., additional

Published
2013
Full Text
View/download PDF

23. Endoscopic mucosal resection of laterally spreading lesions involving the ileocecal valve: technique, risk factors for failure, and outcomes.

Author

Nanda, Kavinderjit S., Tutticci, Nicholas, Burgess, Nicholas G., Sonson, Rebecca, Williams, Stephen J., and Bourke, Michael J.

Subjects
*ENDOSCOPY, *HEALTH outcome assessment, *COLONOSCOPY, *ADENOMA, *CANCER
Abstract

Background and study aims: Endoscopic mucosal resection (EMR) of laterally spreading lesions (LSLs) involving the ileocecal valve (ICV) is technically demanding. Conventionally, these lesions are considered too challenging for endoscopic therapy and are primarily managed surgically. The aims of the study were to describe effectiveness, safety, and outcomes following EMR of LSLs at the ICV. Patients and methods: This was a single-center, prospective, observational, cohort study performed at an academic, tertiary referral center. Patients undergoing EMR for LSLs ≥20mm involving the ICV were recruited over a 5-year period. Standard or cap-assisted colonoscopy with injectand- resect EMR technique was performed with standardized post-EMR management. Procedural success, safety, and outcomes compared with non-ICV LSLs managed during the same period were analyzed. Results: A total of 53 patients with ICV LSLs were referred for EMR (median age 69 years; median lesion size 35.0 mm; 52.8% females). Six patients went directly to surgery because of an endoscopic diagnosis of malignancy (n=2) or technical failure of EMR (n=4). EMR achieved complete adenoma clearance in 44 out of 47 attempted (93.6 %). Surgery was ultimately avoided in 43/53 (81.1 %). Complications included bleeding in 6.4 %. There were no perforations or strictures. Early adenoma recurrence was detected in 7/40 patients (17.5 %), and 1/22 (4.5 %) had late recurrence. All were successfully managed endoscopically. Factors associated with failure of ICV EMR were ileal infiltration and involvement of both ICV lips. Conclusions: In the majority of cases, LSL involving the ICV can be effectively treated by EMR on an outpatient basis. In specialized centers, complications are infrequent, and>80% of patients ultimately avoid surgery. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

24. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Author

O'Meara S, Nanda KS, and Moss AC

Subjects
Clinical Trials as Topic, Humans, Inflammatory Bowel Diseases blood, Infliximab, Infusions, Intravenous, Meta-Analysis as Topic, Prognosis, Risk Factors, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Antibodies, Anti-Idiotypic blood, Antibodies, Monoclonal adverse effects, Drug Hypersensitivity immunology, Inflammatory Bowel Diseases drug therapy
Abstract

Objectives: Antibodies to infliximab (ATIs) have been associated with a risk of infusion reactions in some studies of patients with inflammatory bowel disease. However, many factors, such as immunomodulators and dosing schedule, may influence this association. The aim of this article was to provide a pooled estimate of the risk of infusion reactions according to patients' ATI status and analyze the relationship of immunomodulators to this risk., Design: Public databases were searched for eligible studies. Quality assessment was undertaken for all studies using Grading of Recommendations Assessment, Development and Evaluation criteria. Raw data from studies meeting inclusion criteria were pooled for meta-analysis of effect estimates. Sensitivity analysis was performed for all outcomes. Funnel plot was performed to assess for publication bias., Results: Eight studies met the inclusion criteria, with a pooled total of 1351 subjects. Seven of the 8 studies had a high risk of bias in at least 1 quality domain. The cumulative data indicated that there was a higher risk ratio (RR) of any acute infusion reaction (RR 2.4; 95% confidence interval [CI] 1.5-3.8, P < 0.001) and severe infusion reactions (RR 5.8, 95% CI 1.7-19, P = 0.004) in patients with ATIs when compared with patients without ATIs. The RR of delayed hypersensitivity reactions was not significantly different between ATI+ and ATI- patients (RR 2.8, 95% CI 0.2-33, P = 0.4). Patients prescribed immunomodulators during maintenance infliximab therapy had a reduction in their risk for ATI development (RR 0.6, 95% CI 0.4-0.9, P = 0.02) and infusion reactions (RR 0.6, 95% CI 0.4-0.8, P < 0.001)., Conclusions: The presence of ATIs is associated with a significantly higher risk of acute infusion reactions, but not delayed hypersensitivity reactions, in patients with inflammatory bowel disease. Concomitant immunomodulators reduce this risk.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results